



February 2025



\$4,000,000

Initial Public Offering

Joint Bookrunner



For more information please  
contact :

#### Investment Banking

Gaurav Verma  
Co-Head, Investment Banking  
Direct: +1 (929) 528-0912  
gverma@dboralcapital.com

David Sans  
Senior Managing Director  
Direct: +1 (929) 528-0914  
dsana@dboralcapital.com

Varun Ajarapu  
Analyst  
Direct: +1 (929) 528-0948  
vajjarapu@dboralcapital.com

#### Equity Capital Markets

Philip Wiederlight  
Chief Operating Officer  
Direct: +1 (929) 625-1539  
pwiederlight@dboralcapital.com

Mark Iorio  
Director, Equity Capital Markets  
Direct: +1 (929) 528-0913  
miorio@dboralcapital.com

## D. Boral Capital Served as Joint Bookrunner to Wellgistics Health, Inc. (Nasdaq: WGRX) in connection with its \$4.0 Million Initial Public Offering

### Transaction Information

Tampa, Florida, February 21, 2025 -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 ordinary shares at a public offering price of \$4.50 per ordinary share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and commenced trading on February 21, 2025, under the ticker symbol "WGRX."

The Company received an aggregate of \$4.0 million in gross proceeds from the Offering, before deducting underwriting discounts and other related expenses. The Offering closed on February 24, 2025, subject to the satisfaction of customary closing conditions.

The Offering is being conducted on a firm commitment basis. Craft Capital Management LLC and D. Boral Capital LLC acted as underwriters for the Offering (the "Underwriters"). Dykema Gossett PLLC is acting as securities counsel to the Company, and Sichenzia Ross Ferrance Carmel LLP is acting as securities counsel to the Underwriters in connection with the Offering.

### About Wellgistics Health, Inc.

Wellgistics Health is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. Wellgistics Health is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Wellgistics Health intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from "specialty-lite" to general maintenance conditions. For more information, please visit the Company's website: <https://wellgisticshealth.com/>

### About D. Boral Capital

D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the UAE, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated over \$23 billion in capital since its inception in 2020, executing approximately 300 transactions across a broad range of investment banking products.

